News Column

Findings from Kinki University Faculty of Medicine Broadens Understanding of Cancer Gene Therapy (Successes and limitations of targeted cancer...

July 14, 2014



Findings from Kinki University Faculty of Medicine Broadens Understanding of Cancer Gene Therapy (Successes and limitations of targeted cancer therapy in lung cancer)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting from Osakasayama, Japan, by NewsRx journalists, research stated, "Human cancers usually evolve through multistep processes. These processes are driven by the accumulation of abundant genetic and epigenetic abnormalities."

The news correspondents obtained a quote from the research from the Kinki University Faculty of Medicine, "However, some lung cancers depend on a single activated oncogene by somatic mutation, termed 'driver oncogenic mutations', for their proliferation and survival. EGFR(epidermal growth factor receptor) mutations and ALK(anaplastic lymphoma kinase) rearrangement are typical examples of such driver oncogenic mutations found in lung adenocarcinomas. EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs significantly improved treatment outcomes compared with conventional cytotoxic chemotherapy in patients with lung cancers harboring EGFR mutations or ALK rearrangement, respectively. Therefore, treatment strategies for lung cancers have dramatically changed from a 'general and empiric' to a 'personalized and evidence-based' approach according to the driver oncogenic mutation. Several novel driver oncogenic mutations, which are candidates as novel targets, such as ERBB2, BRAF, ROS1, and RET, have been discovered. Despite these successes, several limitations have arisen. One example is that some lung cancers do not respond to treatments targeting driver oncogenic mutations, as exemplified in KRAS-mutated lung cancers. Another is resistance to molecular-targeted drugs. Such resistance includes de novo resistance and acquired resistance. A number of molecular mechanisms underlying such resistance have been reported. These mechanisms can be roughly divided into three categories: alteration of the targeted oncogenes themselves by secondary mutations or amplification, activation of an alternative oncogenic signaling track, and conversion of cellular characteristics."

According to the news reporters, the research concluded: "Overcoming resistance is a current area of urgent clinical research."

For more information on this research see: Successes and limitations of targeted cancer therapy in lung cancer. Progress In Tumor Research, 2014;41():62-77 (see also Biotechnology).

Our news journalists report that additional information may be obtained by contacting K. Suda, Division of Thoracic Surgery, Dept. of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.

Keywords for this news article include: Asia, Biotechnology, Japan, Kinase, Genetics, Oncology, Osakasayama, Lung Cancer, Lung Neoplasms, Cancer Gene Therapy, Enzymes and Coenzymes.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters